Literature DB >> 33577574

Early dynamic changes in circulating tumor cells and prognostic relevance following interventional radiological treatments in patients with hepatocellular carcinoma.

Thomas J Vogl1, Linda J Riegelbauer2, Elsie Oppermann2, Michel Kostantin2, Hanns Ackermann3, Annette Trzmiel4, Stefan Stein4, Katrin Eichler1, Vladimir P Zharov5, Dhruvajyoti Roy6, Andreas A Schnitzbauer2, Benjamin Strücker7, Andreas Pascher7, Wolf O Bechstein2, Mazen A Juratli2,7.   

Abstract

The aim of this study was to investigate the dynamic changes of circulating tumor cells (CTCs) in patients with hepatocellular carcinoma (HCC) before and immediately after conducting a microwave ablation (MWA) and conventional transarterial chemoembolization (C-TACE). Additionally, the CTCs short-term dynamics were compared with the clinical course of the HCC-patients. Blood samples from 17 patients with HCC who underwent MWA (n = 10) or C-TACE (n = 7) were analyzed. Venous blood was taken before and immediately after the radiological interventions to isolate and quantify CTCs using flow cytometry. CTCs were identified as CD45- and positive for the markers ASGPR, CD146 and CD274 (PD-L1). Patients were followed of up to 2.2 years after the radiological intervention. CTCs were detected in 13 HCC patients (76%) prior to the radiological interventions. The rate of CTCs was significantly decreased after the intervention in patients treated with MWA (0.4 CTCs/mL of blood, p = 0.031). However, no significant differences were observed in patients who received C-TACE (0.3 CTCs/mL of blood, p = 0.300). Overall, no correlation was found between the CTCs rate before and after the radiological intervention and recurrence rate of HCC. This preliminary data could confirm the tumoricidal effects of MWA in patients with HCC by significantly decreasing CTCs rate. In our study, we were able to detect CTCs in HCC patients using 3 different tumor markers. This preliminary data shows significant lower CTCs detected in response to MWA. However, large-scale randomized clinical trials are needed to determine the future role and the prognostic relevance of CTCs following this treatment.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33577574      PMCID: PMC7880472          DOI: 10.1371/journal.pone.0246527

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


  27 in total

Review 1.  Challenges in circulating tumour cell research.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2014-07-31       Impact factor: 60.716

2.  A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.

Authors:  Colin M Court; Shuang Hou; Paul Winograd; Nicholas H Segel; Qingyu Wilda Li; Yazhen Zhu; Saeed Sadeghi; Richard S Finn; Ekambaram Ganapathy; Min Song; Samuel W French; Bita V Naini; Shonan Sho; Fady M Kaldas; Ronald W Busuttil; James S Tomlinson; Hsian-Rong Tseng; Vatche G Agopian
Journal:  Liver Transpl       Date:  2018-07       Impact factor: 5.799

3.  Microwave ablation of primary and secondary liver tumours: ex vivo, in vivo, and clinical characterisation.

Authors:  Claudio Amabile; Muneeb Ahmed; Luigi Solbiati; Maria Franca Meloni; Marco Solbiati; Simone Cassarino; Nevio Tosoratti; Yitzhak Nissenbaum; Tiziana Ierace; S Nahum Goldberg
Journal:  Int J Hyperthermia       Date:  2016-07-25       Impact factor: 3.914

4.  Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study.

Authors:  Ronnie Tung-Ping Poon; Irene Oi-Lin Ng; Cecilia Lau; Wun-Ching Yu; Zhen-Fan Yang; Sheung-Tat Fan; John Wong
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

5.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

Review 6.  Transarterial Therapies for Hepatocellular Carcinoma.

Authors:  Ezio Lanza; Matteo Donadon; Dario Poretti; Vittorio Pedicini; Marco Tramarin; Massimo Roncalli; Hyungjin Rhee; Young Nyun Park; Guido Torzilli
Journal:  Liver Cancer       Date:  2016-11-29       Impact factor: 11.740

7.  Circulating tumor cells measurements in hepatocellular carcinoma.

Authors:  Franck Chiappini
Journal:  Int J Hepatol       Date:  2012-05-28

8.  Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection.

Authors:  Johann von Felden; Kornelius Schulze; Till Krech; Florian Ewald; Björn Nashan; Klaus Pantel; Ansgar W Lohse; Sabine Riethdorf; Henning Wege
Journal:  Oncotarget       Date:  2017-09-23

9.  Real-time monitoring of circulating tumor cell release during tumor manipulation using in vivo photoacoustic and fluorescent flow cytometry.

Authors:  Mazen A Juratli; Mustafa Sarimollaoglu; Eric R Siegel; Dmitry A Nedosekin; Ekaterina I Galanzha; James Y Suen; Vladimir P Zharov
Journal:  Head Neck       Date:  2013-11-29       Impact factor: 3.821

10.  Circulating tumor cells in the central and peripheral venous compartment - assessing hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma.

Authors:  Zhu-Ting Fang; Wei Zhang; Guang-Zhi Wang; Bo Zhou; Guo-Wei Yang; Xu-Dong Qu; Rong Liu; Sheng Qian; Liang Zhu; Ling-Xiao Liu; Jian-Hua Wang
Journal:  Onco Targets Ther       Date:  2014-07-18       Impact factor: 4.147

View more
  6 in total

1.  Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer.

Authors:  Pei-Hung Chang; Chun-Hui Lee; Tyler Min-Hsien Wu; Kun-Yun Yeh; Hung-Ming Wang; Wen-Kuan Huang; Sheng-Chieh Chan; Wen-Chi Chou; Feng-Che Kuan; Hsuan-Chih Kuo; Yung-Chia Kuo; Ching-Chih Hu; Jason Chia-Hsun Hsieh
Journal:  Ther Adv Med Oncol       Date:  2022-07-15       Impact factor: 5.485

Review 2.  Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring.

Authors:  Ivana Martins; Ilda Patrícia Ribeiro; Joana Jorge; Ana Cristina Gonçalves; Ana Bela Sarmento-Ribeiro; Joana Barbosa Melo; Isabel Marques Carreira
Journal:  Genes (Basel)       Date:  2021-02-27       Impact factor: 4.096

Review 3.  Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal.

Authors:  María Lola Espejo-Cruz; Sandra González-Rubio; Javier Zamora-Olaya; Víctor Amado-Torres; Rafael Alejandre; Marina Sánchez-Frías; Rubén Ciria; Manuel De la Mata; Manuel Rodríguez-Perálvarez; Gustavo Ferrín
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

4.  Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma.

Authors:  Zhitao Chen; Tielong Wang; Chuanbao Chen; Xitao Hong; Jia Yu; Yihao Ma; Yiwen Guo; Changjun Huang; Xiaoshun He; Weiqiang Ju; Maogen Chen
Journal:  J Oncol       Date:  2021-10-19       Impact factor: 4.375

5.  Combination of Preoperative Circulating Tumor Cell Count and Neutrophil-Lymphocyte Ratio for Prognostic Prediction in Hepatocellular Carcinoma Patients after Curative Hepatectomy.

Authors:  Hang-Hang Ni; Xi-Hua Yang; Cheng-Lei Yang; Qian Zhang; Jing-Xuan Xu; Lu-Nan Qi; Bang-De Xiang
Journal:  Biomed Res Int       Date:  2022-07-16       Impact factor: 3.246

Review 6.  The Potential of Aptamer-Mediated Liquid Biopsy for Early Detection of Cancer.

Authors:  Dhruvajyoti Roy; Andreas Pascher; Mazen A Juratli; Judith C Sporn
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.